Quick Answer
Acurx Pharmaceuticals, Inc. reported R&D Expense of $1.83 million for fiscal year 2025.
Acurx Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.83M | -66.1% |
| 2024 | $5.40M | -10.6% |
| 2023 | $6.04M | +27.1% |
| 2022 | $4.75M | +134.2% |
| 2021 | $2.03M | -7.8% |
| 2020 | $2.20M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $429.7K | -64.1% | -18.0% |
| June 30, 2025 | $524.2K | -71.3% | -12.5% |
| March 31, 2025 | $598.8K | -61.5% | -50.0% |
| September 30, 2024 | $1.20M | -11.2% | -34.4% |
| June 30, 2024 | $1.83M | +5.1% | +17.4% |
| March 31, 2024 | $1.56M | +53.1% | +15.3% |
| September 30, 2023 | $1.35M | -15.2% | -22.3% |
| June 30, 2023 | $1.74M | +90.5% | +71.0% |
- Acurx Pharmaceuticals, Inc. showed a decrease of -66.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Acurx Pharmaceuticals, Inc.’s r&d expense has declined by 16.7% (from $2.20 million to $1.83 million).
- The most recent figure is from Acurx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: